Familial hypercholesterolaemia - Long-term efficacy and safety of Mipomersen: 2-year interim results


The objective of a study was to evaluate the efficacy and safety of extended dosing with Mipomersen ( Kynamro ) in patients with familial hypercholesterolaemia taking maximally tolerated lipid-lowering therapy.

A planned interim analysis of an ongoing, open-label extension trial in patients ( n = 141 ) with familial hypercholesterolaemia receiving a subcutaneous injection of 200 mg Mipomersen weekly plus maximally tolerated lipid-lowering therapy for up to 104 weeks, was performed.

The mean changes in low-density lipoprotein cholesterol ( LDL-C ) from baseline to weeks 26 ( n = 130 ), 52 ( n = 111 ), 76 ( n = 66 ), and 104 ( n = 53 ) were -28, -27, -27, and -28%; and in apolipoprotein B -29, -28, -30, and -31%, respectively.

Reductions in total cholesterol, non-high-density lipoprotein-cholesterol, and lipoprotein(a) were comparable with decreases in LDL cholesterol and apolipoprotein B levels.

Mean high-density lipoprotein cholesterol increased from baseline by 7 and 6% at weeks 26 and 52, respectively.

The long-term safety profile of Mipomersen was similar to that reported in the associated randomized placebo-controlled phase 3 trials.
Adverse events included injection site reactions and flu-like symptoms.

There was an incremental increase in the median liver fat during the initial 6-12 months that appeared to diminish with continued Mipomersen exposure beyond 1 year and returned towards baseline 24 weeks after last drug dose suggestive of adaptation.
The median alanine aminotransferase ( ALT ) level showed a similar trend over time.

In conclusion, long-term treatment with Mipomersen for up to 104 weeks provided sustained reductions in all atherosclerotic lipoproteins measured and a safety profile consistent with prior controlled trials in these high-risk patient populations. ( Xagena )

Santos RD et al, Eur Heart J 2015;36: 566-575

XagenaMedicine_2015



Indietro

Altri articoli

Subcutaneous administration of Inclisiran, a small-interfering RNA ( siRNA ) directed against proprotein convertase subtilisin/kexin type 9 ( PCSK9 ),...


Two anti-proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) monoclonal antibodies, Alirocumab and Evolocumab, have been approved for the treatment...


A study has compared the efficacy [ low-density lipoprotein cholesterol ( LDL-C ) lowering ] and safety of Alirocumab (...


Proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) binds to LDL receptors, leading to their degradation. Genetics studies have shown...


Homozygous familial hypercholesterolaemia ( HoFH ) is a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein...


IMPROVE-IT ( IMProved Reduction of Outcomes: VYTORIN Efficacy International Trial ), was an international, multi-center, randomised, double-blind active comparator trial...


Statins ( HMG-CoA reductase inhibitors ) are widely used medicines for patients with lipid disorders and in the primary and...


Patients with homozygous familial hypercholesterolaemia respond inadequately to existing drugs. A study has assessed the efficacy and safety of the...


On 13 December 2012, the Committee for Medicinal Products for Human Use ( CHMP ) has adopted a negative opinion,...